Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Smokey1958on Apr 04, 2021 9:28pm
204 Views
Post# 32935756

RE:the boat has sailed......

RE:the boat has sailed......Seajust, for you and others like you.

https://www.bbc.com/news/56100076

From this article ....

John Nkengasong, head of the Africa Centres for Disease Control and Prevention (CDC), says the vaccines provided under the Covax scheme "will not get the pandemic out" of the continent without further assistance.

He says African countries will eventually need to vaccinate at least 60% of their populations, with his target for this year being 35%.

As of 15 March, only 23.6 million doses of vaccine had been distributed on the continent, the Africa CDC says.

This is equivalent to around 1.7% of the population.

Therefore testing will be required on a mass scale for at least the next year or two ...if not longer.

While I don't expect you to understand the numbers, reports are now out that the world's population will not be vaccinated for years. Further to this the article doesn't even take into consideration Central and South America. Further to that, most of the tests you state (and then state nothing about them) will not meet the litmus test for mass appeal. Even if a handful do, there are hundreds of millions of school kids, workers, health care practioners around the world where testing will be required until they are vaccinated.

SeaMonkey, you haven't found, nor have you provided, any credible evidence to support your drivel ....thankfully, by responding to you the collective has demonstrated quite clearly to those who are still a little unsure as to why the risk on investing in THRMs AcuVid is a reasonable risk to assume ...particularly because of the potential for significant return.

Thank you for being the catalyst for this.

seajust wrote: and someone is still on the dock.

https://www.medscape.com/viewarticle/948626


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse